Alx oncology reports encouraging clinical data of evorpacept in combination with standard-of-care in an ongoing phase 1/2 clinical trial in patients with relapsed or refractory b-cell non-hodgkin lymphoma (“r/r b-nhl”)

– twenty patients with indolent (n=18) and aggressive (n=2) r/r b-nhl received evorpacept plus standard rituximab and lenalidomide (“r2”)– evorpacept plus r2 was well tolerated with a safety profile similar to historical r2 – the combination achieved promising initial activity with a best overall response rate (“orr”) of 94% and a complete response rate (“crr”) of 83% in patients with indolent r/r b-nhl (r2 historical crr benchmark is 34%)
ALXO Ratings Summary
ALXO Quant Ranking